News

BioSpace3h
FDA Greenlights Jazz’s Dordaviprone, First New Treatment for Ultra-Rare Brain Tumor
The small molecule drug, acquired by Jazz Pharmaceuticals in its $935 million Chimerix pick-up this spring, is intended for ...
The American Journal of Managed Care3h
FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma
Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive ...
US FDA approves Jazz Pharma's drug for rare brain tumor
The U.S. Food and Drug Administration said on Wednesday that it has approved Jazz Pharmaceuticals' drug to treat diffuse ...
MedPage Today2h
FDA Approves Brain Tumor Drug Targeting New Mutation
The FDA granted accelerated approval to dordaviprone (Modeyso) as the first systemic therapy for adults and children with ...
Arthritis Treatment Reduces Painful Flare-Ups, Slows Disease
Researchers envisage the final version as an injection that could be personalized to each patient to improve effectiveness.
New procedure offers youthful hands with platelet-rich plasma treatment
CINCINNATI (WKRC) — A cutting-edge procedure is gaining popularity for those seeking to reduce signs of aging on their hands. Dr. Elizabeth Muennich of Dermatology & Skin Care Associates explained the ...
Medscape2h
FDA Approves Drug for Aggressive Glioma
Jazz Pharmaceuticals bet $1 billion on the commercial potential of a first-in-class oral imipridone for recurrent H3 K27M-mutant diffuse glioma.
TipRanks on MSN8h
Pfizer’s New Study on Ponsegromab: A Potential Breakthrough in Pancreatic Cancer Treatment
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. has announced a new clinical study titled ‘A Phase 2b/3, ...